Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 1
1962 4
1963 3
1964 2
1965 1
1966 1
1967 1
1969 2
1970 2
1971 1
1972 4
1973 3
1974 5
1976 1
1977 1
1980 1
1981 2
1982 2
1983 5
1984 5
1985 2
1986 3
1987 4
1988 9
1989 12
1990 4
1991 9
1992 3
1993 7
1994 1
1995 4
1996 2
1997 4
1998 7
1999 14
2000 16
2001 13
2002 8
2003 4
2004 6
2005 8
2006 12
2007 17
2008 14
2009 21
2010 17
2011 19
2012 20
2013 16
2014 30
2015 34
2016 42
2017 44
2018 48
2019 33
2020 30
2021 28
2022 18
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

557 results
Results by year
Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. Among authors: oki y. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Horwitz SM, et al. Among authors: oki y. Blood. 2018 Feb 22;131(8):888-898. doi: 10.1182/blood-2017-08-802470. Epub 2017 Dec 12. Blood. 2018. PMID: 29233821 Free PMC article. Clinical Trial.
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Evens AM, et al. Among authors: oki y. Haematologica. 2022 May 1;107(5):1086-1094. doi: 10.3324/haematol.2021.278438. Haematologica. 2022. PMID: 34162178 Free PMC article.
NK-Cell Lymphomas.
Chihara D, Oki Y. Chihara D, et al. Among authors: oki y. Cancer Treat Res. 2019;176:163-184. doi: 10.1007/978-3-319-99716-2_8. Cancer Treat Res. 2019. PMID: 30596218
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. Kim SJ, et al. Among authors: oki y. Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10. Lancet Oncol. 2016. PMID: 26873565
Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021.
Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa S, Ichijo T, Otsuki M, Omura M, Ogawa Y, Oki Y, Kurihara I, Kobayashi H, Sakamoto R, Satoh F, Takeda Y, Tanaka T, Tamura K, Tsuiki M, Hashimoto S, Hasegawa T, Yoshimoto T, Yoneda T, Yamamoto K, Rakugi H, Wada N, Saiki A, Ohno Y, Haze T. Naruse M, et al. Among authors: oki y. Endocr J. 2022 Apr 28;69(4):327-359. doi: 10.1507/endocrj.EJ21-0508. Epub 2022 Apr 12. Endocr J. 2022. PMID: 35418526 Free article.
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Wang M, et al. Among authors: oki y. Leukemia. 2013 Sep;27(9):1902-9. doi: 10.1038/leu.2013.95. Epub 2013 Apr 2. Leukemia. 2013. PMID: 23545991 Clinical Trial.
Decitabine--bedside to bench.
Oki Y, Aoki E, Issa JP. Oki Y, et al. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. doi: 10.1016/j.critrevonc.2006.07.010. Epub 2006 Oct 4. Crit Rev Oncol Hematol. 2007. PMID: 17023173 Review.
Novel treatments for T-cell lymphoma.
Cheah CY, Oki Y, Fanale MA. Cheah CY, et al. Among authors: oki y. Am Soc Clin Oncol Educ Book. 2015:e468-78. doi: 10.14694/EdBook_AM.2015.35.e468. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993211 Free article. Review.
557 results